Evidence map›Paper›PMID 41479990›Full record

ArticleWorld journal of cardiology2025

Bleeding prediction by rotational thromboelastometry in chronic hemodialysis patients with non-valvular atrial fibrillation on apixaban.

Dimitra Bacharaki, Elias Kyriakou, Aggeliki Sardeli, Petros Nikolopoulos, George Triantaphyllis, Athina Drakou, Fotis Makris, Eleni Spanou, Eleni Triantou, Emmanouel Haviaras and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of cardiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Dimitra BacharakiClinical and Interventional Nephrology Unit, Attikon University General Hospital, Chaidari 12462, Attikí, Greece. bacharaki@gmail.com.
Elias KyriakouDepartment of Laboratory Hematology, Hemostasis and Transfusion Services, Attikon University General Hospital, Chaidari 12462, Attikí, Greece.
Aggeliki SardeliClinical and Interventional Nephrology Unit, Attikon University General Hospital, Chaidari 12462, Attikí, Greece.
Petros NikolopoulosClinical and Interventional Nephrology Unit, Attikon University General Hospital, Chaidari 12462, Attikí, Greece.
George TriantaphyllisHemodialysis Unit, Medifil AE Private Nephrological Centre, Peristeri 12132, Attikí, Greece.
Athina DrakouNephrology Unit, Henry Dunant Hospital Center, Athens 11526, Attikí, Greece.
Fotis MakrisHemodialysis Unit, Mesogeios Palaiou Falirou, Palaio Faliro 17564, Attikí, Greece.
Eleni SpanouHemodialysis Unit, Protypo Nephrology Center Piraeus, Piraeus 18454, Attikí, Greece.
Eleni TriantouNephrology Unit, Henry Dunant Hospital Center, Athens 11526, Attikí, Greece.
Emmanouel HaviarasHemodialysis Unit, Medifil AE Private Nephrological Centre, Peristeri 12132, Attikí, Greece.
Alexandra FatourouHemodialysis Unit, Mesogeios Palaiou Falirou, Palaio Faliro 17564, Attikí, Greece.
Aristarchos PoulisDepartment of Laboratory Hematology, Hemostasis and Transfusion Services, Attikon University General Hospital, Chaidari 12462, Attikí, Greece.
Argyrios TsantesDepartment of Laboratory Hematology, Hemostasis and Transfusion Services, Attikon University General Hospital, Chaidari 12462, Attikí, Greece.
John KyriazisDepartment of Nephrology, General Hospital of Chios, Chios 82100, Chios Regional Unit, Greece.
Sophia LionakiClinical and Interventional Nephrology Unit, Attikon University General Hospital, Chaidari 12462, Attikí, Greece.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe use of apixaban in chronic hemodialysis (HD) patients for non-valvular atrial fibrillation (NVAF) is still controversial regarding benefit of stroke protection

aimTo determine whether bleeding risk can be predicted using ROTEM activated with tissue factor (EXTEM) in HD patients receiving apixaban for NVAF.

methodsNineteen HD patients with NVAF treated with apixaban for at least 8 days were enrolled. Four dosing regimens were recorded as prescribed by their physician, from 2.5 mg once daily on a non-dialysis day to 5 mg twice daily. Standard coagulation tests, along with ROTEM and apixaban drug levels (using liquid anti-Xa assay) were performed once on a non-dialysis day before and two hours after apixaban morning pill administration. Patients were subsequently monitored for thrombotic/bleeding events and all-cause mortality.

resultsOver a median follow-up period of 36 months, six patients experienced a bleeding event (group A) and 13 remained free of bleeding (group B). Six deaths were recorded: Three due to major bleeding, one from thrombotic stroke, and two unrelated to coagulopathy. EXTEM clotting time (CT)-post was the only parameter that significantly differed between group A and group B (

conclusionEarly detection of bleeding risk in HD patients with NVAF on Apixaban maybe be effectively achieved through frequent monitoring using ROTEM EXTEM post CT, thereby helping to reduce associated morbidity.

Indexed as

ApixabanBleedingChronic hemodialysisNon valvular atrial fibrillationPlatelet function assayPredictionRotational thromboelastometry

Identifiers

PMID41479990
PMCPMC12754064

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.